Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05843292 | Short-term Sintilimab in Combination With Taxane and Carboplatin for Neoadjuvant Therapy in Triple-negative Breast Cancer(NeoSTEP) | not yet recruiting | Phase 4 | 48 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | Jun 6, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 |
| clinicaltrials |
| NCT05447702 | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | recruiting | Phase 2 | 35 | West China HospitalOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05795335 | CDK4/6 Inhibitors in Patients With Hormone Receptor-positive Advanced Breast Cancer | recruiting | — | 172 | RenJi HospitalOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT05851014 | A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer | recruiting | Phase 3 | 350 | Genor Biopharma Co., Ltd.INDUSTRY | 1 | May 9, 2023 | clinicaltrials |
| NCT05841381 | Adjuvant Study of Pyrotinib in Combination With Trastuzumab in HER2 Positive Invasive Breast Cancer | not yet recruiting | Phase 3 | 876 | Fudan UniversityOTHER | 0 | May 3, 2023 | clinicaltrials |
| NCT05841849 | Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer | not yet recruiting | Phase 4 | 1,028 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05834764 | Pyrotinib in Women With High-risk in Early Stage Breast Cancer | recruiting | Phase 2 | 188 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05835739 | InheriteD brEast caNcer iTalian regIsTrY A Retrospective-prospective Observational Cohort Study to Evaluate Cancer Prevention Strategies in Women With a Deleterious Mutation in BRCA1-2(IDENTITY) | recruiting | — | 78 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Apr 28, 2023 | clinicaltrials |
| NCT05833659 | Comparison Between Prepectoral and Subpectoral Breast Reconstruction(RESPECT) | recruiting | — | 88 | Beijing Friendship HospitalOTHER | 1 | Apr 27, 2023 | clinicaltrials |
| NCT04800393 | The Impact of Inhalation vs Total Intravenous Anesthesia on the Immune Status and Mortality in Patients Undergoing Breast Cancer Surgery: a Prospective Double-Blind Randomized Clinical Trial.(TeMP) | recruiting | N/A | 130 | Moscow Clinical Scientific CenterOTHER | 1 | Apr 26, 2023 | clinicaltrials |
| NCT05212454 | Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks | recruiting | Phase 3 | 400 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Apr 25, 2023 | clinicaltrials |
| NCT05452213 | Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients(CAPTOR-BC) | recruiting | Phase 4 | 1,000 | Institut fuer FrauengesundheitOTHER | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05804916 | Optical Surface Monitoring Technology-Guided Large-Segment Radiotherapy for Breast Cancer | recruiting | Phase 2 / Phase 3 | 556 | Peking Union Medical College HospitalOTHER | 1 | Apr 7, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT01763125 | Establishment of a Tumor Bank for Blood Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 4 | Mar 23, 2023 | clinicaltrials |
| NCT01789229 | Establishment of a Tumor Bank for Tissue Samples | recruiting | — | 10,000 | Medical University of ViennaOTHER | 3 | Mar 23, 2023 | clinicaltrials |
| NCT05638594 | Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer | recruiting | Phase 2 | 236 | Shengjing HospitalOTHER | 1 | Mar 20, 2023 | clinicaltrials |
| NCT05732051 | Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients(NARNIA) | recruiting | Phase 2 | 60 | University Hospital, AkershusOTHER | 1 | Mar 17, 2023 | clinicaltrials |
| NCT05766410 | A Randomized Study Comparing the Immune Modulation Effect of Ribociclib, Palbociclib, and Abemaciclib in ER+/HER2- EBC(ORACLE-RIPA) | recruiting | Phase 2 | 60 | National Taiwan University HospitalOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT04483804 | Application of Radiomics in Breast Cancer | recruiting | — | 2,000 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05762900 | Ultra-hypofractioNated Adjuvant Radiotherapy ± sImultaneous Integrated Boost for Low-risk Breast Cancer Patients(UNIQUE) | recruiting | Phase 2 | 65 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT05218044 | Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ(DCIS) | recruiting | N/A | 30 | Glendale Adventist Medical Center d/b/a Adventist Health GlendaleOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT05753657 | A Pilot Study of Monitoring Insulin Levels and Treating Hyperinsulinemia and Hyperglycemia With Pioglitazone in Patients Treated With Alpelisib for Metastatic Breast Cancer. | recruiting | Early Phase 1 | 30 | Rambam Health Care CampusOTHER | 1 | Mar 3, 2023 | clinicaltrials |
| NCT03436069 | Identification of New Prognostic Markers for Breast Cancer.(PROBREAST) | recruiting | — | 1,500 | University Hospital, GrenobleOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04690439 | Photobiomodulation Therapy for the Management of Breast Cancer-related Lymphedema(LymphLight) | recruiting | N/A | 104 | Jessa HospitalOTHER | 1 | Feb 28, 2023 | clinicaltrials |
| NCT04501523 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC(Apollo) | recruiting | Phase 2 | 460 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT04803539 | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC(Artemis) | recruiting | Phase 2 / Phase 3 | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2023 | clinicaltrials |
| NCT05730647 | Prospective Observational Study of Adjuvant Hormone Treatment in Estrogen-receptor Positive Premenopausal Early Breast Cancer Patients(GIM 23- POSTER) | active not recruiting | — | 600 | Consorzio OncotechOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05731258 | Observational of Adjuvant Treatment of Breast Cancer With Liposomal Doxorubicin Regimen | recruiting | — | 150 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Feb 16, 2023 | clinicaltrials |
| NCT05462457 | TAD in Primary Breast Cancer With Initially ≥ 3 Suspicious Lymph Nodes(SenTa2) | recruiting | — | 150 | Kliniken Essen-MitteOTHER | 1 | Feb 15, 2023 | clinicaltrials |
| NCT02306538 | Evaluation of Myocardial Changes During BReast Adenocarcinoma Therapy to Detect Cardiotoxicity Earlier With MRI(EMBRACE-MRI) | active not recruiting | — | 180 | University Health Network, TorontoOTHER | 1 | Feb 14, 2023 | clinicaltrials |
| NCT05698186 | Thero2-01S22 in HER2-positive Breast Cancer | not yet recruiting | Phase 3 | 320 | Institut de cancérologie Strasbourg EuropeOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT02400658 | Efficacy of IORT With CT-Guided HDR Brachytherapy for Treatment of Breast Cancer | active not recruiting | N/A | 358 | Shayna Showalter, MDOTHER | 1 | Jan 25, 2023 | clinicaltrials |
| NCT05692674 | A Prospective Phase II Study for Adjuvant Hypofractionated Intensity-modulated Proton Radiotherapy for Post Operative Breast Cancer With Implantation Reconstruction | recruiting | Phase 2 | 67 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Jan 20, 2023 | clinicaltrials |
| NCT02261389 | Follow-up of Early Breast Cancer by Dynamic Evaluation of CEA and CA 15.3 Followed by 18FDG-PET | active not recruiting | N/A | 1,507 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT05665920 | Efficacy and Safety of Ultra_HYPofractionated RadiotHerapy in Women With BrEast CaNcer Receiving Regional Nodal Radiation vs Nodal Moderate Hypofractionated Radiotherapy(HYPHEN) | recruiting | N/A | 36 | Instituto Brasileiro de Controle do CancerOTHER | 1 | Dec 29, 2022 | clinicaltrials |
| NCT04472845 | HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-risk Patients With Breast Cancer (HYPART).(HYPART) | recruiting | N/A | 1,018 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | Dec 8, 2022 | clinicaltrials |
| NCT05627960 | First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies | recruiting | Phase 1 | 77 | A&G Pharmaceutical Inc.INDUSTRY | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05613504 | Study of Acupuncture in the Treatment of Hot Flashes in Patients With Hormone Receptor-positive Breast Cancer. | not yet recruiting | N/A | 90 | Nanjing University of Traditional Chinese MedicineOTHER | 1 | Nov 16, 2022 | clinicaltrials |
| NCT03150576 | Platinum and Polyadenosine 5'Diphosphoribose Polymerisation Inhibitor for Neoadjuvant Treatment of Triple Negative Breast Cancer and/or Germline BRCA Positive Breast Cancer(PARTNER) | recruiting | Phase 2 / Phase 3 | 780 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Nov 14, 2022 | clinicaltrials |
| NCT05502224 | Multidisciplinary Approach to Fatigue | recruiting | N/A | 50 | Jules Bordet InstituteOTHER | 1 | Nov 8, 2022 | clinicaltrials |
| NCT05603078 | A Prospective Study of Preoperative Tumor-bed Boost Followed by Oncoplastic Surgery and Adjuvant Whole Breast Radiotherapy for Early Stage Breast Cancer (BIRKIN)(BIRKIN) | recruiting | N/A | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05587777 | Monitoring of Chronic Conditions in Breast Cancer(REBECCA-1) | recruiting | — | 150 | Helse Stavanger HFOTHER_GOV | 1 | Oct 20, 2022 | clinicaltrials |
| NCT01057069 | Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer(neo-TN) | active not recruiting | Phase 2 / Phase 3 | 310 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT01646034 | High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer(Oligo) | active not recruiting | Phase 3 | 74 | The Netherlands Cancer InstituteOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04263298 | Fulvestrant Versus Capecitabine as Maintenance Therapy After First-line Chemotherapy in Patients With HR+/HER2- Metastatic Breast Cancer | recruiting | Phase 3 | 210 | Herui YaoOTHER | 1 | Sep 30, 2022 | clinicaltrials |
| NCT05541367 | Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer | recruiting | — | 80 | Tongji HospitalOTHER | 1 | Sep 15, 2022 | clinicaltrials |
| NCT04983121 | Efficacy and Safety of Pyrotinib Maleate Combined With ARX788 Neoadjuvant Treatment in Breast Cancer Patients | recruiting | Phase 2 | 30 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05228951 | Pyrotinib Maleate, Trastuzumab, SHR6390 and Letrozole in Combination for Stage II-III TPBC | recruiting | Phase 2 | 12 | Shengjing HospitalOTHER | 1 | Sep 13, 2022 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2023source: clinicaltrials